ReviewThe Journal of physiology2011
Effects of recombinant human erythropoietin in normal humans.
Review in The Journal of physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01584921 (Renal Effects of Erythropoietin in Humans), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Renal Effects of Erythropoietin in Humans
Who cites it
30 citing papers in PubMed, 84 citations in OpenAlex.
- Recombinant erythropoietin acutely decreases renal perfusion and decouples the renin-angiotensin-aldosterone system.Physiological reports · 2018Trial
- Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.BMC neurology · 2017Trial
- Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.Journal of Korean medical science · 2014Trial
- Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.PloS one · 2014Trial
- Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.PloS one · 2013Trial
- Erythropoiesis-Targeted Doping in Sports: From Improved Oxygen Transport to Cardiovascular Risk.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Metabolomic responses are more sensitive in muscle than serum following 28 days of arduous exercise with erythropoietin administration.Experimental physiology · 2026Article
- Cardiovascular Implications of the Enhanced Games: Performance Enhancing Drugs in Competition and Recreation.Sports medicine - open · 2026Review
- Acute and Intermittent Exogenous Ketosis to Support Recovery From Exercise and Adaptations to Exercise Training: A Narrative Review.Scandinavian journal of medicine & science in sports · 2025Review
- Strenuous training combined with erythropoietin induces red cell volume expansion-mediated hypervolemia and alters systemic and skeletal muscle iron homeostasis.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Article
- Exogenous erythropoietin increases hematological status, fat oxidation, and aerobic performance in males following prolonged strenuous training.Physiological reports · 2024Article
- Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.Cardio-oncology (London, England) · 2023Review
- Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent.European journal of case reports in internal medicine · 2023Article
- The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor.Frontiers in molecular neuroscience · 2023Article
- Does Hypoxia and Stress Erythropoiesis Compromise Cardiac Function in Healthy Adults? A Randomized Trial.Sports medicine - open · 2022Article
- The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise.Pflugers Archiv : European journal of physiology · 2021Article
- Neurostimulation, doping, and the spirit of sport.Neuroethics · 2021Article
- No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men.Endocrine connections · 2020Article
- A Single 60.000 IU Dose of Erythropoietin Does Not Improve Short-Term Aerobic Exercise Performance in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Frontiers in physiology · 2020Article
- Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction.Physiological reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review describes some of the physiological effects of recombinant human erythropoietin (EPO) in healthy humans. At the blood level EPO increases the arterial O(2) content not only by increasing red blood cell volume, but also by an equally important decrease in plasma volume. Well before that, EPO causes a prompt decrease in plasma levels of renin and aldosterone. Renal clearance studies suggest that EPO decreases renal proximal tubular reabsorption rate leading to activation of the tubuloglomerular feedback mechanism and a fall in glomerular filtration rate. Thus, treatment with EPO may result in suppression of endogenous EPO production through a decrease in intrarenal oxygen consumption. EPO elevates the arterial blood pressure even in healthy subjects. The receptor for EPO is present in many tissues. However, the functional effects of EPO in the skeletal muscle seem limited, and although it has been speculated that non-erythropoietic effects of EPO (angiogenesis, shift in muscle fibre types, cognitive effects) may be responsible for the increase in exercise performance, this has not been confirmed. EPO-induced haemodynamic effects call for careful monitoring during the administration period. The metabolic, hormonal and renal effects of EPO do not seem to range beyond physiologically acceptable limits and are reversible. Taken together, EPO seems safe to use for experimental purposes in healthy volunteers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.